XML 81 R40.htm IDEA: XBRL DOCUMENT v3.3.1.900
Licensing and Commercialization Agreement with Novartis Pharma AG (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 7 Months Ended 12 Months Ended
May. 19, 2014
Apr. 30, 2015
Mar. 31, 2015
Oct. 31, 2014
Sep. 30, 2014
May. 31, 2014
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Agreement                              
Total collaboration revenue             $ 4,782 $ 3,448 $ 1,597 $ 41,678 $ 1,684 $ 39,575   $ 51,505 $ 41,259
License revenue                              
Agreement                              
Total collaboration revenue                           38,083 38,373
Research and development activity revenue                              
Agreement                              
Total collaboration revenue                           8,378 2,000
API transfer revenue                              
Agreement                              
Total collaboration revenue                           5,020 883
Joint operating committee revenue                              
Agreement                              
Total collaboration revenue                           24 $ 3
Novartis Pharma AG                              
Agreement                              
Upfront fees received           $ 200,000                  
Patient enrollment-based milestone revenue achieved     $ 50,000   $ 50,000               $ 100,000    
Licensing and Commercialization Agreement | Novartis Pharma AG                              
Agreement                              
Upfront fees received $ 200,000                            
Licensing and Commercialization Agreement | Novartis Pharma AG | Achievement of specified patient enrollment milestones                              
Agreement                              
Milestone payment received   $ 50,000   $ 50,000                      
Patient enrollment-based milestone revenue achieved     $ 50,000   $ 50,000               $ 100,000    
Recognized revenues                           51,500  
Licensing and Commercialization Agreement | Novartis Pharma AG | Achievement of specified patient enrollment milestones | Maximum                              
Agreement                              
Aggregate amount receivable on achievement of milestone             130,000             130,000  
Licensing and Commercialization Agreement | Novartis Pharma AG | Achievement of specified regulatory approval milestones | Maximum                              
Agreement                              
Aggregate amount receivable on achievement of milestone             300,000             300,000  
Licensing and Commercialization Agreement | Novartis Pharma AG | Achievement of specified commercial sale milestone | Maximum                              
Agreement                              
Aggregate amount receivable on achievement of milestone             $ 400,000             $ 400,000